xenograft model antitumor assays

Summary

Summary: In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.

Top Publications

  1. ncbi Stable suppression of tumorigenicity by Pin1-targeted RNA interference in prostate cancer
    Akihide Ryo
    Department of Pathology, Yokohama City University School of Medicine, Yokohama, Japan
    Clin Cancer Res 11:7523-31. 2005
  2. ncbi NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
    Violeta Serra
    Laboratory of Oncology Research, Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Cancer Res 68:8022-30. 2008
  3. ncbi ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
    Christophe Ginestier
    Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
    Cell Stem Cell 1:555-67. 2007
  4. ncbi Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
    Sauveur Michel Maira
    Oncology Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH4002 Basel, Switzerland
    Mol Cancer Ther 7:1851-63. 2008
  5. ncbi Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases
    Frank Winkler
    E.L. Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
    Cancer Cell 6:553-63. 2004
  6. ncbi Hypoxia--a key regulatory factor in tumour growth
    Adrian L Harris
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Nat Rev Cancer 2:38-47. 2002
  7. ncbi Oncolytic vaccinia therapy of squamous cell carcinoma
    Zhenkun Yu
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mol Cancer 8:45. 2009
  8. ncbi BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    Scott M Wilhelm
    Bayer Pharmaceuticals Corporation, West Haven, Connecticut 06516, USA
    Cancer Res 64:7099-109. 2004
  9. ncbi Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus
    Qian Zhang
    Genelux Corporation, San Diego Science Center, San Diego, California 92109, USA
    Cancer Res 67:10038-46. 2007
  10. ncbi Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent
    I Gentschev
    Genelux Corporation, San Diego Science Center, San Diego, CA 92109, USA
    Cancer Gene Ther 16:320-8. 2009

Research Grants

  1. Effect of HIV-1 Vpr on Basic Cellular Functions (II)
    Richard Zhao; Fiscal Year: 2007
  2. ENHANCING RADIATION THERAPY: VASCULAR TARGETING AGENTS
    Dietmar Siemann; Fiscal Year: 2007
  3. RADIATION AND DRUG EFFECTS ON TUMOR CELL SUBPOPULATIONS
    Dietmar Siemann; Fiscal Year: 2001
  4. Combining Anti Angiogenesis Strategies and Radiotherapy
    Dietmar Siemann; Fiscal Year: 2005
  5. Radioimmunotherapy of CD20+ Lymphomas & CD45+Leukemias
    JOHN PAGEL; Fiscal Year: 2007
  6. Combining Anti-Angiogenesis Strategies and Radiotherapy
    Dietmar W Siemann; Fiscal Year: 2010
  7. ENHANCING RADIATION THERAPY: VASCULAR TARGETING AGENTS
    Dietmar W Siemann; Fiscal Year: 2010
  8. Bone Marrow Transplantation for Hematologic Malignancies using Novel Radioimmunot
    John M Pagel; Fiscal Year: 2010
  9. Minimal-disease radioimmunotherapy of colorectal cancer
    Serengulam Govindan; Fiscal Year: 2003
  10. GRSA Proteins in the Diagnosis of Breast Cancer
    WILLIAM NORTH; Fiscal Year: 2002

Detail Information

Publications247 found, 100 shown here

  1. ncbi Stable suppression of tumorigenicity by Pin1-targeted RNA interference in prostate cancer
    Akihide Ryo
    Department of Pathology, Yokohama City University School of Medicine, Yokohama, Japan
    Clin Cancer Res 11:7523-31. 2005
    ..In the present study, we sought to determine the potential of Pin1-targeted gene silencing in inhibiting cellular growth and tumorigenicity in prostate cancer...
  2. ncbi NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
    Violeta Serra
    Laboratory of Oncology Research, Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Cancer Res 68:8022-30. 2008
    ..In summary, NVP-BEZ235 inhibits the PI3K/mTOR axis and results in antiproliferative and antitumoral activity in cancer cells with both wild-type and mutated p110-alpha...
  3. ncbi ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
    Christophe Ginestier
    Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
    Cell Stem Cell 1:555-67. 2007
    ..These findings offer an important new tool for the study of normal and malignant breast stem cells and facilitate the clinical application of stem cell concepts...
  4. ncbi Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
    Sauveur Michel Maira
    Oncology Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH4002 Basel, Switzerland
    Mol Cancer Ther 7:1851-63. 2008
    ..Collectively, the preclinical data show that NVP-BEZ235 is a potent dual PI3K/mTOR modulator with favorable pharmaceutical properties. NVP-BEZ235 is currently in phase I clinical trials...
  5. ncbi Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases
    Frank Winkler
    E.L. Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
    Cancer Cell 6:553-63. 2004
    ..During the normalization window, but not before or after it, VEGFR2 blockade increases pericyte coverage of brain tumor vessels via upregulation of Ang1 and degrades their pathologically thick basement membrane via MMP activation...
  6. ncbi Hypoxia--a key regulatory factor in tumour growth
    Adrian L Harris
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Nat Rev Cancer 2:38-47. 2002
    ..Many elements of the hypoxia-response pathway are therefore good candidates for therapeutic targeting...
  7. ncbi Oncolytic vaccinia therapy of squamous cell carcinoma
    Zhenkun Yu
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mol Cancer 8:45. 2009
    ..We examined the therapeutic effects of an attenuated, replication-competent vaccinia virus (GLV-1h68) as an oncolytic agent against a panel of six human head and neck SCC cell lines...
  8. ncbi BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    Scott M Wilhelm
    Bayer Pharmaceuticals Corporation, West Haven, Connecticut 06516, USA
    Cancer Res 64:7099-109. 2004
    ..These data demonstrate that BAY 43-9006 is a novel dual action RAF kinase and VEGFR inhibitor that targets tumor cell proliferation and tumor angiogenesis...
  9. ncbi Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus
    Qian Zhang
    Genelux Corporation, San Diego Science Center, San Diego, California 92109, USA
    Cancer Res 67:10038-46. 2007
    ..These findings suggest that immune activation may combine with viral oncolysis to induce tumor eradication in this model, providing a novel perspective for the design of oncolytic viral therapies for human cancers...
  10. ncbi Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent
    I Gentschev
    Genelux Corporation, San Diego Science Center, San Diego, CA 92109, USA
    Cancer Gene Ther 16:320-8. 2009
    ..This is the first report demonstrating that vaccinia virus is an effective tool for the therapy of canine mammary cancers, which might next be applied to dogs with breast tumors...
  11. ncbi Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts
    Christina L Roland
    Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390 8593, USA
    Mol Cancer Ther 8:1761-71. 2009
    ..These findings further define the complex molecular interactions in the tumor microenvironment and provide a translational tool that may be relevant to the treatment of breast cancer...
  12. ncbi Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation
    Xuerong Wang
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Cancer Res 68:7409-18. 2008
    ..Consequently, the sustained Akt activation during mTOR inhibition will counteract the anticancer efficacy of the mTOR inhibitors...
  13. ncbi Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235
    Douglas W McMillin
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 69:5835-42. 2009
    ..g., dexamethasone and doxorubicin) or novel (e.g., bortezomib) anti-MM agents showed lack of antagonism. These results indicate that BEZ235 merits clinical testing, alone and in combination with other agents, in MM...
  14. ncbi Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo
    Hua Chen
    The Hepatosplenic Surgery Center, Department of General Surgery, The First Clinical Medical School of Harbin Medical University, Harbin, China
    Anticancer Drugs 20:131-40. 2009
    ..This study indicates that DHA may be a potent and promising agent to combat pancreatic cancer...
  15. ncbi Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model
    Puja Sapra
    Enzon Pharmaceuticals, Inc, Piscataway, New Jersey 08854, USA
    Clin Cancer Res 14:1888-96. 2008
    ..We have developed a novel polymer-drug conjugate, EZN-2208, made by linking SN38 with a multiarm polyethylene glycol via a glycine linker...
  16. ncbi Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
    Jing Qing
    Department of Molecular Oncology, Genentech Inc, South San Francisco, California, USA
    J Clin Invest 119:1216-29. 2009
    ..These studies provide in vivo evidence demonstrating an oncogenic role of FGFR3 in bladder cancer and support antibody-based targeting of FGFR3 in hematologic and epithelial cancers driven by WT or mutant FGFR3...
  17. ncbi Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo
    Madeleine S Q Kortenhorst
    Prostate Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, James Buchanan Brady Urological Institute, School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA
    Mol Cancer Ther 8:802-8. 2009
    ..Therefore, nuclear structural alterations may serve as a biomarker for histone deacetylase inhibitor treatment...
  18. ncbi DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity
    Rachelle S Singleton
    Auckland Cancer Society Research Centre, The University of Auckland, Auckland, New Zealand
    Cancer Res 69:3884-91. 2009
    ....
  19. ncbi Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging
    Christian R Schnell
    Oncology Disease Area, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Cancer Res 68:6598-607. 2008
    ....
  20. ncbi Atg5 regulates phenethyl isothiocyanate-induced autophagic and apoptotic cell death in human prostate cancer cells
    Ajay Bommareddy
    Department of Pharmacology and Chemical Biology, and University of Pittsburgh Cancer Institute, Pennsylvania, USA
    Cancer Res 69:3704-12. 2009
    ..In conclusion, the present study indicates that Atg5 plays an important role in regulation of PEITC-induced autophagic and apoptotic cell death...
  21. ncbi Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a β-galactosidase-activatable prodrug seco-analog of duocarmycin SA
    C M Seubert
    Department of Biochemistry, University of Wurzburg, Germany
    Cancer Gene Ther 18:42-52. 2011
    ..Moreover, in vivo, additional prodrug treatment had beneficial effects on tumor regression in GLV-1h68-treated GI-101A-xenografted mice...
  22. ncbi Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma
    Randall W Alfano
    Cancer Research Institute, Scott and White Memorial Hospital, Temple, Texas 76502, USA
    Mol Cancer Ther 9:190-201. 2010
    ..Therefore, the MMP-activated LeTx could be used not only in the clinical management of V600E B-Raf ATC but potentially in any solid tumor...
  23. ncbi Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion
    Akira Orimo
    Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
    Cell 121:335-48. 2005
    ..Our findings indicate that fibroblasts within invasive breast carcinomas contribute to tumor promotion in large part through the secretion of SDF-1...
  24. ncbi Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity
    Nripen Chanda
    Department of Radiology, Harry S Truman Veterans Administration Medical Center, Columbia, MO, USA
    Proc Natl Acad Sci U S A 107:8760-5. 2010
    ....
  25. ncbi Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program
    Peter J Houghton
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Pediatr Blood Cancer 54:921-6. 2010
    ..IMC-A12 is a fully human IgG1 antibody that prevents ligand binding to the IGF-1R...
  26. ncbi Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer
    Xiong Cai
    Curis Inc, 45 Moulton Street, Cambridge, Massachusetts 02138, USA
    J Med Chem 53:2000-9. 2010
    ....
  27. ncbi Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance
    Nathan T Ihle
    M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 69:143-50. 2009
    ....
  28. ncbi Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action
    Junmei Hou
    Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences Graduate School of the Chinese Academy of Sciences, Shanghai 200031, People s Republic of China
    Clin Cancer Res 14:5519-30. 2008
    ..However, the mechanisms underlying these activities remain unclear. This study was designed to determine their antitumor efficacy and underlying mechanisms of action in human hepatoma cells...
  29. ncbi Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer
    Yun Su
    Department of Surgery, Zhongda Hospital, The School of Clinical Medicine, Southeast University, Nanjing, China
    Cancer Epidemiol Biomarkers Prev 19:327-37. 2010
    ..ALDH1A1 may serve as a useful marker for monitoring the progression of bladder tumor and identifying bladder cancer patients with poor prognosis who might benefit from adjuvant and effective treatments...
  30. ncbi Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68
    Yong A Yu
    Genelux Corporation, San Diego Science Center, 3030 Bunker Hill Street, Suite 310, San Diego, CA 92109, USA
    Mol Cancer Ther 8:141-51. 2009
    ..In conclusion, the GLV-1h68 strain showed outstanding therapeutic effects and a documented safety profile in mice, with great promise for future clinical development...
  31. ncbi Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma
    Dan Huang
    Laboratory of Cancer Genetics, Laboratory of Computational Biology, Van Andel Research Institute, Grand Rapids, Michigan 49503, USA
    Cancer Res 70:1063-71. 2010
    ..Our results reveal IL-8 as an important contributor to sunitinib resistance in ccRCC and a candidate therapeutic target to reverse acquired or intrinsic resistance to sunitinib in this malignancy...
  32. ncbi Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer
    Jeroen T Buijs
    Department of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands
    Cancer Res 67:8742-51. 2007
    ..Because exogenous BMP7 can still counteract the breast cancer growth at the primary site and in bone, BMP7 may represent a novel therapeutic molecule for repression of local and bone metastatic growth of breast cancer...
  33. ncbi Proteomics identification of cyclophilin a as a potential prognostic factor and therapeutic target in endometrial carcinoma
    Zhengyu Li
    Department of Gynecology and Obstetrics, West China Second corrected Hospital, Sichuan University, Chengdu 610041, China
    Mol Cell Proteomics 7:1810-23. 2008
    ..01) and the inhibition of tumor growth in vivo (p < 0.01). These data suggest that cyclophilin A may serve as a novel prognostic factor and possibly an attractive therapeutic target for endometrial carcinoma...
  34. ncbi A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
    Michael M Schmidt
    Department of Biological Engineering, Massachusetts Institute of Technology, Building E19 551, 50 Ames Street, Cambridge, MA 02139, USA
    Mol Cancer Ther 8:2861-71. 2009
    ..All model predictions are shown to be consistent with experimental observations from published targeting studies. The results and techniques have implications for drug development, imaging, and therapeutic dosing...
  35. ncbi Hyaluronan: from extracellular glue to pericellular cue
    Bryan P Toole
    Department of Cell Biology and Anatomy, Medical University of South Carolina, 173 Ashley Avenue, Charleston, South Carolina 29425, USA
    Nat Rev Cancer 4:528-39. 2004
  36. ncbi Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy
    Jyotsnabaran Halder
    Department of Gynecologic Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 12:4916-24. 2006
    ..CONCLUSIONS: Taken together, these findings suggest that FAK siRNA-DOPC plus docetaxel or platinum might be a novel therapeutic approach against ovarian cancer...
  37. ncbi Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter
    David Dingli
    Molecular Medicine Program, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Blood 103:1641-6. 2004
    ..Testing in other radiosensitive cancers is warranted...
  38. ncbi Antiangiogenic effects of noscapine enhance radioresponse for GL261 tumors
    Elizabeth W Newcomb
    Department of Pathology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    Int J Radiat Oncol Biol Phys 71:1477-84. 2008
    ..To assess the effects of noscapine, a tubulin-binding drug, in combination with radiation in a murine glioma model...
  39. ncbi In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762
    James B Mitchell
    Radiation Biology and Radiation Oncology Branches, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Clin Cancer Res 16:2076-84. 2010
    ..A novel checkpoint kinase 1/2 inhibitor, AZD7762, was evaluated for potential enhancement of radiosensitivity for human tumor cells in vitro and in vivo xenografts...
  40. ncbi A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication
    Robert E Edge
    Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa Health Research Institute, Centre for Cancer Therapeutics, Ottawa, Ontario, Canada
    Mol Ther 16:1437-43. 2008
    ....
  41. ncbi Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo
    Yihong Zhang
    Department of Oncology Research, Amgen, Inc, Thousand Oaks, California 91320, USA
    Cancer Res 68:6680-7. 2008
    ....
  42. ncbi Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells
    Vinata B Lokeshwar
    Division of Urology Research, Department of Urology M 800, University of Miami Miller School of Medicine, P O Box 016960, Miami, FL 33101, USA
    Cancer Res 70:2613-23. 2010
    ..Therefore, the anticancer effects of 4-MU, an orally bioavailable and relatively nontoxic agent, are primarily mediated by inhibition of HA signaling...
  43. ncbi Molecular characterization of the pediatric preclinical testing panel
    Geoffrey Neale
    Hartwell Center of Bioinformatics and Biotechnology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Clin Cancer Res 14:4572-83. 2008
    ..Identifying novel therapeutic agents for the treatment of childhood cancers requires preclinical models that recapitulate the molecular characteristics of their respective clinical histotypes...
  44. ncbi FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism
    Andrea Valentine
    School of Pharmacy, Queen s University Belfast, Belfast, United Kingdom
    Clin Cancer Res 17:1044-56. 2011
    ..Antiangiogenic therapies can be an important adjunct to the management of many malignancies. Here we investigated a novel protein, FKBPL, and peptide derivative for their antiangiogenic activity and mechanism of action...
  45. ncbi Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68
    Ivaylo Gentschev
    Genelux Corporation, San Diego Science Center, San Diego, CA 92109, USA
    J Biomed Biotechnol 2010:489759. 2010
    ..Our data documented that the GLV-1h68 virus has a great potential for treatment of human prostate carcinoma...
  46. ncbi Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer
    Kwang Woon Kim
    Department of Radiation Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Autophagy 4:659-68. 2008
    ..Our report suggests that combined inhibition of apoptosis and mTOR during radiotherapy is a potential therapeutic strategy to enhance radiation therapy in patients with non-small cell lung cancer...
  47. ncbi Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity
    Cory Allen
    Molecular Medicine Department, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Mol Ther 16:1556-64. 2008
    ..Strains of measles virus retargeted against the glioma-specific IL-13Ralpha2 receptor have comparable therapeutic efficacy, and improved specificity as compared with the unmodified measles virus strain MV-GFP in vitro and in vivo...
  48. ncbi Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers
    Iduna Fichtner
    Max Delbruck Center for Molecular Medicine, Berlin Buch, Germany
    Clin Cancer Res 14:6456-68. 2008
    ..It was the aim of our study to establish an extensive panel of non-small cell lung cancer (NSCLC) xenograft models useful for the testing of novel compounds and for the identification of biomarkers...
  49. ncbi A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity
    John E Weldon
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 4264, USA
    Blood 113:3792-800. 2009
    ..We conclude that HA22-LR advances the therapeutic efficacy of HA22 by using an approach that may be applicable to other PE-based immunotoxins...
  50. ncbi Treatment of breast cancer through the application of irreversible electroporation using a novel minimally invasive single needle electrode
    Robert E Neal
    Bioelectromechanical Systems Lab, Virginia Tech Wake Forest School of Biomedical Engineering and Sciences, Virginia Tech, 329 ICTAS Building, MC0298, Stranger Street, Blacksburg, VA 24061, USA
    Breast Cancer Res Treat 123:295-301. 2010
    ..Tumor regression was observed in 5 out of 7 MDA-MB231 human mammary tumors orthotopically implanted in female Nu/Nu mice, with continued growth in controls...
  51. ncbi Curcumin inhibits tumor growth and angiogenesis in glioblastoma xenografts
    Marie Claude Perry
    Laboratoire de Medecine Moleculaire, Université du Québec à Montréal Hôpital Sainte Justine, Montreal, Canada
    Mol Nutr Food Res 54:1192-201. 2010
    ..The mechanisms of the anti-tumor effects of curcumin were related, at least partly, to the inhibition of glioma-induced angiogenesis...
  52. ncbi Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines
    K A Olaussen
    INSERM, U848, Villejuif, France
    Oncogene 28:4249-60. 2009
    ..Such combinations may lead to a 'collapse' of pro-survival signal transduction pathways that leads to apoptotic cell death...
  53. ncbi Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations
    Georgia Konstantinidou
    Division of Hematology and Oncology, Simmons Comprehensive Cancer Center, and Hamon Center for Therapeutic Oncology Research, Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas TX 75390, USA
    Cancer Res 69:7644-52. 2009
    ..These findings may have general applicability in cancer therapy, because aberrant activation of PI3K occurs frequently in human cancer...
  54. ncbi Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab
    Sabrina Höbel
    Department of Pharmacology and Toxicology, Philipps University School of Medicine, D 35032 Marburg, Germany
    J Gene Med 12:287-300. 2010
    ..Vascular endothelial growth factor (VEGF) is frequently overexpressed in tumors and promotes tumor growth, angiogenesis and metastasis and thus represents an attractive target gene in tumor therapy...
  55. ncbi Lin-28B expression promotes transformation and invasion in human hepatocellular carcinoma
    Yun Chu Wang
    Graduate Institute of Pathology, National Taiwan University, Taipei 100, Taiwan
    Carcinogenesis 31:1516-22. 2010
    ..These results indicate that Lin-28B regulates tumor formation and invasion in HCC through coordinated repression of the let-7/mir-98 family and induction of multiple oncogenic pathways...
  56. ncbi The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models
    Mark J Williamson
    Millennium Pharmaceuticals, Cambridge, MA 02139, USA
    Mol Cancer Ther 8:3234-43. 2009
    ....
  57. ncbi Characterization of TEM1/endosialin in human and murine brain tumors
    Eleanor B Carson-Walter
    Department of Neurosurgery, The University of Rochester, Rochester, NY, USA
    BMC Cancer 9:417. 2009
    ..We characterized the expression pattern of TEM1/endosialin in astrocytic and metastatic brain tumors and investigated its role as a therapeutic target in human endothelial cells and mouse xenograft models...
  58. ncbi Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice
    Sharmila Shankar
    Department of Biochemistry, Center for Biomedical Research, The University of Texas Health Science Center at Tyler, 11937 U S Highway 271, Tyler, TX 75708 3154, USA
    Mol Cancer Ther 8:1596-605. 2009
    ..In conclusion, sequential treatment with SAHA followed by TRAIL may target multiple pathways in tumor progression, angiogenesis, and metastasis and represents a novel therapeutic approach to treat breast cancer...
  59. ncbi The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3
    Christopher P Guise
    Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Auckland, New Zealand
    Cancer Res 70:1573-84. 2010
    ..A survey of normal tissue AKR1C3 expression suggests the potential for tumor-selective PR-104A activation by this mechanism. These findings have significant implications for the clinical development of PR-104...
  60. ncbi Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer
    Christopher P Gully
    Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer 9:42. 2010
    ..However, this compound has not been evaluated in breast cancer, the second leading cause of cancer deaths among women...
  61. ncbi Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche
    Janine T Erler
    Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Cancer Cell 15:35-44. 2009
    ..CD11b+ cells and LOX also colocalize in biopsies of human metastases. Our findings demonstrate a critical role for LOX in premetastatic niche formation and support targeting LOX for the treatment and prevention of metastatic disease...
  62. ncbi Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma
    Meike Vogler
    University Children s Hospital, Ulm University, Ulm, Germany
    Cancer Res 69:2425-34. 2009
    ..These findings build the rationale for further (pre)clinical development of XIAP inhibitors and TRAIL against pancreatic cancer...
  63. ncbi Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 in ovarian cancer
    Peng Liu
    Departments of Experimental Pathology, University of British Columbia, Vancouver, British Columbia, Canada
    Cancer Res 69:4843-50. 2009
    ..Collectively, these results indicate that vHNF1 acts as a repressor of HSulf-1 expression and might be a molecular target for ovarian cancer therapy...
  64. ncbi Efficient inhibition of ovarian cancer growth and prolonged survival by transfection with a novel pro-apoptotic gene, hPNAS-4, in a mouse model. In vivo and in vitro results
    Fan Yang
    Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu, PR China
    Oncology 75:137-44. 2008
    ..We transfected ovarian cancer cells and administered recombinant plasmid encoding hPNAS-4 to nude mice bearing ovarian cancer, aiming to evaluate the effect of hPNAS-4 against ovarian cancer in vitro and in vivo...
  65. ncbi Cytosporone B is an agonist for nuclear orphan receptor Nur77
    Yanyan Zhan
    Key Laboratory of the Ministry of Education for Cell Biology and Tumor Cell Engineering, School of Life Sciences, Xiamen University, 422 South Siming Road, Xiamen, Fujian 361005, China
    Nat Chem Biol 4:548-56. 2008
    ..Thus, Csn-B may represent a promising therapeutic drug for cancers and hypoglycemia, and it may also be useful as a reagent to increase understanding of Nur77 biological function...
  66. ncbi Chemoprevention by perillyl alcohol coupled with viral gene therapy reduces pancreatic cancer pathogenesis
    Irina V Lebedeva
    Department of Urology, Herbert Irving Comprehensive Cancer Center, Columbia University, College of Physicians and Surgeons, New York, New York, USA
    Mol Cancer Ther 7:2042-50. 2008
    ..This novel and innovative approach combining a dietary agent and a virally delivered therapeutic cytokine provides a means of both preventing and treating human pancreatic cancer with significant clinical translational potential...
  67. ncbi A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity
    Alessia Montagnoli
    Nerviano Medical Sciences Oncology, Via Pasteur 10, 20014 Nerviano, Italy
    Nat Chem Biol 4:357-65. 2008
    ....
  68. ncbi Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo
    Vincent K W Wong
    Department of Chemistry, The University of Hong Kong, China
    Clin Cancer Res 11:6002-11. 2005
    ..Furthermore, we showed that PAB circumvents P-glycoprotein overexpression-induced drug resistance and is effective in inhibiting tumor growth in vivo. Our work will facilitate the future development of PAB as a cancer therapeutic...
  69. ncbi Preclinical study of a "tailor-made" combination of NK4-expressing gene therapy and gefitinib (ZD1839, Iressa) for disseminated peritoneal scirrhous gastric cancer
    Yoshihisa Namiki
    Institute of Clinical Medicine and Research, The Jikei University School of Medicine, Kashiwa, Chiba, Japan
    Int J Cancer 118:1545-55. 2006
    ..0001) and time to euthanasia (days) (control, 36.5; treated, 56; p < 0.0001) were also significantly prolonged. This combination is a potentially useful approach to the treatment of peritoneal gefitinib-sensitive SGC dissemination...
  70. ncbi Genistein inhibits invasive potential of human hepatocellular carcinoma by altering cell cycle, apoptosis, and angiogenesis
    Yan Gu
    Department of General Surgery, The Ninth People s Hospital, Shanghai Second Medical University, Shanghai, China
    World J Gastroenterol 11:6512-7. 2005
    ..To study the in vitro and in vivo inhibitory effects of genistein on invasive potential of Bel 7402 hepatocellular carcinoma (HCC) cells and to explore the underlying mechanism...
  71. ncbi [The combination of octreotide to rofecoxib enhanced the inhibitory effect on growth of human hepatocellular carcinoma]
    Chun-lun Liu
    Department of Gastroenterology, The First Hospital, Chongqing Medical University, Chongqing 400016, China
    Zhonghua Nei Ke Za Zhi 42:313-5. 2003
    ..Octreotide combined with rofecoxib greatly enhanced the anti-growth effects on HCC in vivo when compared with rofecoxib alone. These synergic results may be of potential therapeutic benefit to those patients with non-resectable HCC...
  72. ncbi Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts
    K Jin Kim
    Galaxy Biotech, LLC, Mountain View, California 94033, USA
    Clin Cancer Res 12:1292-8. 2006
    ..Thus, an anti-HGF monoclonal antibody (mAb) capable of blocking the HGF-Met interaction could have broad applicability in cancer therapy...
  73. ncbi Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo
    Laurence Maggiorella
    , 94805 Villejuif, Cedex, France
    Cancer Res 63:2513-7. 2003
    ..In conclusion, we found a novel effect on DNA repair of the CDK inhibitor roscovitine, which acts as a radiosensitizer in vitro and in vivo in breast cancer cells lacking a functional p53...
  74. ncbi Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors)
    Yumiko Hirokawa
    Ludwig Institute for Cancer Research, Melbourne Branch, P O Box 2008, Royal Melbourne Hospital, Parkville Melbourne 3050, Australia
    Cancer Lett 245:242-51. 2007
    ..Also, this PP1/GL-2003 combination therapy has been proven to be very effective to suppress the estrogen-independent growth of an NF1-deficient multidrug/FK228-resistant human breast cancer (MDA-MB-231) xenograft in mice...
  75. ncbi Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases
    H Tada
    Department of Surgery, Division of Surgical Oncology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
    J Clin Invest 108:83-95. 2001
    ..The toxicity of an adenoviral vector expressing murine IFN-beta in a syngeneic model is also presented. These encouraging results warrant further investigation of the use of cancer gene therapy for targeting metastatic disease...
  76. ncbi Adenovirus-mediated p53 treatment enhances photodynamic antitumor response
    Dae-Seog Lim
    Cancer Research Institute of Medical Science, The Catholic University of Korea, Seoul 137-040, South Korea
    Hum Gene Ther 17:347-52. 2006
    ....
  77. ncbi Caspase-1 as a radio- and chemo-sensitiser in vitro and in vivo
    Pilar Martin-Duque
    Cancer Research UK Molecular Oncology Unit, Bart s and The London School of Medicine and Dentistry, John Vane Science Centre, UK
    Int J Mol Med 17:841-7. 2006
    ..Caspase-1 mediated sensitisation to cisplatin and gamma-radiation was also observed in vivo. Altogether, we conclude that caspase-1 can act as a radio- and chemo-sensitiser, in vitro and in vivo...
  78. ncbi Enhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide
    S Naito
    Department of Oral and Maxillofacial Surgery II, Osaka University Graduate School of Dentistry, Suita, Osaka, Japan
    Cancer Gene Ther 13:780-91. 2006
    ..Hexamethylene bisacetamide can be used as an enhancing agent for oncolytic therapy with HSV-1 mutants...
  79. ncbi Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids
    Karuppaiyah Selvendiran
    Research Center for Innovative Cancer Therapy, and Center of the 21st Century Center of Excellence Program for Medical Science, Kurume University, Kurume, Japan
    Cancer Res 66:4826-34. 2006
    ....
  80. ncbi [Effects of inhibition of cyclooxygenase-2 by RNA interference on proliferation and apoptosis of human gastric cancer cells: an experimental study with human gastric cancer cells and mice]
    Bu-hai Wang
    Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
    Zhonghua Yi Xue Za Zhi 86:266-71. 2006
    ....
  81. ncbi Molecule action mechanisms of NM-3 on human gastric cancer SGC-7901 cells in vivo or in vitro
    Jin Shui Zhu
    Department of Gastroenterology, Affiliated Sixth People s Hospital, Shanghai Jiaotong University, Shanghai 200233, China
    World J Gastroenterol 9:2366-9. 2003
    ..To study the molecule action mechanisms of NM-3 on the growth of human gastric cancer SGC-7901 cells in vivo or in vitro...
  82. ncbi Suicide gene/prodrug therapy for pancreatic adenocarcinoma by E. coli purine nucleoside phosphorylase and 6-methylpurine 2'-deoxyriboside
    Sophie Deharvengt
    INSERM U375, Strasbourg Cedex, France
    Pancreas 28:E54-64. 2004
    ..CONCLUSION: These preliminary results support the therapeutic potential of the MePdR/ePNP system, which induces a highly cytotoxic effect with a potent bystander effect on pancreatic tumors...
  83. ncbi Enhanced growth suppression of Philadephia1 leukemia cells by targeting bcr3/abl2 and VEGF through antisense strategy
    X L Cong
    State Key Laboratory of Experimental Hematology, National Research Center for Stem Cell Engineering and Technology, Tianjin, China
    Leukemia 19:1517-24. 2005
    ..These results demonstrate that targeting both bcr3/abl2 and VEGF can result in an additive tumor-suppressive action and may represent an excellent strategy to augment the efficacy of chemotherapy in CML...
  84. ncbi Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis
    Gang jun Du
    Department of Pharmacology, Pharmacy College of He nan University, Kaifeng 475001, He Nan, China
    Vascul Pharmacol 43:112-9. 2005
    ..Effect of thalidomide on COX-1 and COX-2 in vivo was consistent with that of in vitro. These results demonstrated that thalidomide might inhibit growth of tumors through COX-2 degradation independent of antiangiogenesis...
  85. ncbi Anticancer effect and apoptosis induction of gambogic acid in human gastric cancer line BGC-823
    Wei Liu
    Department of Physiology, China Pharmaceutical University, Nanjing 210009, Jiangsu Province, China
    World J Gastroenterol 11:3655-9. 2005
    ..The result was also confirmed in vivo...
  86. ncbi Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma
    Thomas C Stover
    Department of Pharmacology, Pennsylvania State College of Medicine, Hershey, Pennsylvania 17033, USA
    Clin Cancer Res 11:3465-74. 2005
    ..Together, these results indicate that bioactive ceramide analogues can be incorporated into pegylated liposomal vehicles for improved solubility, drug delivery, and antineoplastic efficacy...
  87. ncbi Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models
    Debra Ferguson
    Abbott Laboratories, Abbott Park, Illinois 60064, USA
    Clin Cancer Res 11:3045-54. 2005
    ....
  88. ncbi Gene transfer of inhibitor kappaB in human lung cancer cell line NCI-H460 inhibits tumorigenesis and angiogenesis in vivo
    Jian Ni
    Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka 812-8582, Japan
    Anticancer Res 25:69-77. 2005
    ..CONCLUSION: Adenovirus-mediated IkappaBalpha gene transfer is a promising cancer treatment strategy...
  89. ncbi Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8
    Koji Harada
    Second Department of Oral and Maxillofacial Surgery, University of Tokushima, School of Dentistry, Tokushima 770 8504, Japan
    Int J Oncol 27:1489-97. 2005
    ..These findings suggest that vesnarinone can suppress the angiogenesis and growth of oral squamous cell carcinoma cells by inhibiting the expression of VEGF and IL-8 involved in blockade of NF-kappaB activity...
  90. ncbi Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting
    Pablo Matar
    Laboratory of Oncology Research, Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 10:6487-501. 2004
    ..CONCLUSIONS: Our findings suggest both shared and complementary mechanisms of action with gefitinib and cetuximab and support combined EGFR targeting as a clinically exploitable strategy...
  91. ncbi Peritoneal metastasis inhibition by linoleic acid with activation of PPARgamma in human gastrointestinal cancer cells
    Takamitsu Sasaki
    Department of Molecular Pathology, Nara Medical University, Kashihara, Japan
    Virchows Arch 448:422-7. 2006
    ..These findings suggest that LA inhibits invasion and metastasis of human gastric and colon cancer cells by nondietary administration...
  92. ncbi A novel retinoid, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), induces apoptosis of human ovarian carcinoma cells and shows potential as a new antitumor agent for clear cell adenocarcinoma
    Nao Suzuki
    Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo, Japan
    Gynecol Oncol 94:643-9. 2004
    ..We examined the antitumor activity of TAC-101 against human ovarian carcinoma cell lines...
  93. ncbi Effect of polypeptides in bee venom on growth inhibition and apoptosis induction of the human hepatoma cell line SMMC-7721 in-vitro and Balb/c nude mice in-vivo
    Haiyang Hu
    School of Pharmacy 42 mailbox, Shenyang Pharmaceutical University, Liaoning, 110016, RP China
    J Pharm Pharmacol 58:83-9. 2006
    ..5 or 3 mg kg(-1)) resulted in a significant retardation of SMMC-7721 cell growth in Balb/c nude mice. These findings suggested that PBV could be used as a chemotherapeutic agent against tumours...
  94. ncbi Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer
    Roberto Bianco
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, , Naples, Italy
    Clin Cancer Res 10:4858-64. 2004
    ....
  95. ncbi [Inhibitory effect of antisense oligodeoxynucleotides targeting HER-2 mRNA on growth of breast cancer: experiment in vivo with mice]
    Jun-Zhong Sun
    No. 304 Clinical Department, General Hospital of Chinese People's Liberation Army, Beijing 100039, China
    Zhonghua Yi Xue Za Zhi 86:540-3. 2006
    ..CONCLUSION: Antisense oligodeoxynucleotides targeting HER-2 mRNA inhibits the growth of breast cancer in a sequence specific and dose-dependent manner...
  96. ncbi Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma
    Zhuoying Wang
    Department of Head and Neck Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, 77030-4009, USA
    Clin Cancer Res 12:4755-65. 2006
    ..CONCLUSION: Blocking the IGF-IR with A12 seems to be a potential avenue for treating patients with ATC by its direct antitumor effects and its effects on the tumor vasculature...
  97. ncbi Combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts
    Satoshi Anai
    Department of Urology, University of Florida, Gainesville 32610, USA
    Hum Gene Ther 17:975-84. 2006
    ....
  98. ncbi Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program
    John M Maris
    Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine and Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania, USA
    Pediatr Blood Cancer 50:581-7. 2008
    ..This study was designed to screen for antitumor activity of AZD2171 against the in vitro and in vivo childhood cancer preclinical models of the Pediatric Preclinical Testing Program (PPTP)...
  99. ncbi [Effect of ZGDHu-1 on proliferation and apoptosis of A549 cells in vitro and antitumor activity in vivo]
    Yong lie Zhou
    Central Laboratory, Zhejiang Provincial People s Hospital, Hangzhou 310014, China
    Yao Xue Xue Bao 42:26-34. 2007
    ..The mechanism may associate with its up-regulation of bax and p53 during the apoptosis process...
  100. ncbi Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma
    P Neri
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Leukemia 21:2519-26. 2007
    ..Taken together, these data demonstrate the in vitro and in vivo antitumor activity of Atip, delineate potential molecular targets triggered by this agent, and provide a preclinical rational for its clinical evaluation in MM...
  101. ncbi Anti-tumor potential of 15,16-dihydrotanshinone I against breast adenocarcinoma through inducing G1 arrest and apoptosis
    Sun Lung Tsai
    Liver Research Unit, Department of Medical Research, Chi Mei Medical Center, Yung Kang City, Tainan, Taiwan
    Biochem Pharmacol 74:1575-86. 2007
    ..Taken together, these results suggest that DHTS can inhibit human breast cancer cell proliferation and tumor growth, and might have potential chemotherapeutic applications...

Research Grants147 found, 100 shown here

  1. Effect of HIV-1 Vpr on Basic Cellular Functions (II)
    Richard Zhao; Fiscal Year: 2007
    ..abstract_text> ..
  2. ENHANCING RADIATION THERAPY: VASCULAR TARGETING AGENTS
    Dietmar Siemann; Fiscal Year: 2007
    ....
  3. RADIATION AND DRUG EFFECTS ON TUMOR CELL SUBPOPULATIONS
    Dietmar Siemann; Fiscal Year: 2001
    ..Ultimately we hope that these approaches can be reliably developed to an extent where the use of human tumor biopsy material may lead to radiotherapy treatments more tailored to the individual patient. ..
  4. Combining Anti Angiogenesis Strategies and Radiotherapy
    Dietmar Siemann; Fiscal Year: 2005
    ..We believe that these studies will provide essential insights into the therapeutic utility of employing antiangiogenic treatment strategies as adjuvants to radiotherapy. ..
  5. Radioimmunotherapy of CD20+ Lymphomas & CD45+Leukemias
    JOHN PAGEL; Fiscal Year: 2007
    ..abstract_text> ..
  6. Combining Anti-Angiogenesis Strategies and Radiotherapy
    Dietmar W Siemann; Fiscal Year: 2010
    ..Experiments are designed to investigate the mechanisms underlying the interaction between such therapies and to develop approaches that would maximize the anti-tumor efficacy of such combined treatments. ..
  7. ENHANCING RADIATION THERAPY: VASCULAR TARGETING AGENTS
    Dietmar W Siemann; Fiscal Year: 2010
    ..Experiments are designed to investigate how to deliver such therapies for maximum antitumor efficacy as well as determining the potential of developing predictive indicators of their treatment response. ..
  8. Bone Marrow Transplantation for Hematologic Malignancies using Novel Radioimmunot
    John M Pagel; Fiscal Year: 2010
    ..We anticipate that these approaches will cure more patients and cause fewer toxicities than currently available therapies. ..
  9. Minimal-disease radioimmunotherapy of colorectal cancer
    Serengulam Govindan; Fiscal Year: 2003
    ..Successful feasibility study will lead to extended preclinical therapy studies and the initiation of a clinical Phase I RAIT trial in a SBIR Phase II program. ..
  10. GRSA Proteins in the Diagnosis of Breast Cancer
    WILLIAM NORTH; Fiscal Year: 2002
    ..These methods could be applicable to all patients with breast cancer or suspected breast cancer. ..
  11. MAb-based targeted chemotherapy of lung cancer
    Serengulam Govindan; Fiscal Year: 2007
    ..The ultimate goal of the proposed project is to develop a safer and more efficacious targeted therapy of non-small-cell lung cancer using a tumor-selective antibody and the active drug form of the cancer therapeutic, CPT-11. ..
  12. THE ROLE OF HORMONES IN HEALTH AND DISEASE
    WILLIAM NORTH; Fiscal Year: 2007
    ..The ETP alsoprovides acenter for improved teaching and health delivery for Northern New England. ..
  13. Bispecific Antibody Pretargeting for Therapy
    ROBERT SHARKEY; Fiscal Year: 2007
    ..Anti-antibody responses will also be measured to the humanized bsMAb. This clinical trial will be conducted at the Fox Chase Cancer Center. ..
  14. COORDINATED REGULATION OF ANTIOXIDANT ENZYMES
    Michael Kelner; Fiscal Year: 2005
    ..abstract_text> ..
  15. INVESTIGATION INTO PARAQUAT CYTOTOXICITY
    Michael Kelner; Fiscal Year: 1993
    ..The mechanism and cellular level (DNA, RNA, protein synthesis) by which this cell continues to express glutathione peroxidase, even when exposed to paraquat, will be determined...
  16. RAPAMYCIN INDUCED SELECTIVE APOPTOSIS IN MALIGNANT CELLS
    Peter Houghton; Fiscal Year: 2002
    ..The long-term goal of these studies is to develop alternative curative therapy for children with cancer that will avoid the often devastating events, associated with contemporary intensive chemo-radiotherapy regimens. ..
  17. Bispecific Antibody Pretargeted Therapy of Pancreatic Cancer
    ROBERT SHARKEY; Fiscal Year: 2007
    ..e., cetuximab and erlotinib) can further enhance this combination. Overall, these studies will assist in establishing whether this type of pretargeting approach could have a role in the clinical management of pancreatic cancer. ..
  18. PHASE I TRIAL OF A PEPTIDE VACCINE AGAINST EGFRVIII
    Bruce Montgomery; Fiscal Year: 2005
    ..To characterize effects of human anti-EGFRvIII antibodies on EGFRvIII signaling. 4. To determine the level of EGFR specific T cell response after immunization with EGFRvIII peptide. ..
  19. Cell Cycle G2/M Pathway Modulated by Viral Protein R
    Richard Zhao; Fiscal Year: 2006
    ..These proposed studies will provide a comprehensive framework for this new cell cycle control pathway and provide insights into fundamental aspects of this new G2/M surveillance system of eukaryotic cells. ..
  20. Development of Reagents for Labeling with At-211
    DANIEL WILBUR; Fiscal Year: 2007
    ..abstract_text> ..
  21. Effect of HIV-1 Vpr on Basic Cellular Functions (II)
    Richard Zhao; Fiscal Year: 2003
    ..abstract_text> ..
  22. STUDIES OF CHILDHOOD SOLID TUMORS
    Peter Houghton; Fiscal Year: 2007
    ..Our intent remains to advance preclinical information to the design of clinical trials, and extend these to cooperative groups. ..
  23. Effect of HIV-1 Vpr on Basic Cellular Functions (II)
    Richard Zhao; Fiscal Year: 2006
    ..abstract_text> ..
  24. Development of At-211-Labeled Reagents for Therapy of Metastatic Prostate Cancer
    DANIEL SCOTT WILBUR; Fiscal Year: 2010
    ..The proposed research will develop new and unique At-211-labeled reagents that have the potential to dramatically improve the five-year survival of prostate cancer patients with metastatic disease. ..
  25. The MiT Transcription Factor in Pediatric Malignancies
    David Fisher; Fiscal Year: 2007
    ..Small molecules inhibitors of c-MET exist and will be examined (together with molecular controls) as potential targeted therapy for these incurable cancers. ..
  26. P13K/AKT crosstalk with ER-signaling and cell survival
    Matthew Burow; Fiscal Year: 2007
    ..This cross-talk and the mechanisms identified will be used to establish the biological relevancy of the Dathway in terms of cell survival and altered SERM activity, ..
  27. Mitf-Signal Responsive Transcription in Osteoclasts
    David Fisher; Fiscal Year: 2009
    ..The second represents a systematic approach to the identification of transcriptional targets of Mitf/TFE3 using screens which couple their biochemical activities to the signaling pathways in which they reside. ..
  28. MI--A MASTER GENE FOR MELANOCYTE DEVELOPMENT
    David Fisher; Fiscal Year: 2000
    ....
  29. The Development of Vitamin D as a Therapy for Breast Cancer
    David Feldman; Fiscal Year: 2009
    ..This strategy will provide a safe and economical improvement to the usual therapeutic regimen administered to BCa patients. ..
  30. Angiopoietin-2 and Glioma Invasion
    Shi Yuan Cheng; Fiscal Year: 2007
    ..These studies could establish Ang2 and its effectors as potential therapeutic targets leading to the development of new anti-invasion strategies for glioma treatments. ..
  31. Tumor suppressor adenomatous polyposis coli and breast carcinogenesis
    Satya Narayan; Fiscal Year: 2007
    ....
  32. Rapamycin-induced Selective Apoptosis in Malignant Cells
    Peter Houghton; Fiscal Year: 2009
    ..The studies have the potential to radically alter outcome for these children, and reduce the debilitating sequellae of high dose radiation and chemotherapy. ..